Shionogi & Co. Ltd.
http://www.shionogi.co.jp/index.html
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Shionogi & Co. Ltd.
Asia Deal Watch: Orum, Vertex Team Up On Gene Editing Conditioning Agents
Plus deals involving Eisai/Sato, Keymed/Belenos, Taiho/Arcus, IASO/Innovent, Biocytogen/SOTIO, Ensol/Spine, TMS/Hokkaido University and Yuhan/Ubix.
Chiesi Takes Long View To Build Japan Rare Disease Presence
After expanding its local portfolio through acquisitions and partnerships, Chiesi is now aiming to build its presence in Japan's rare disease sector over the long term, helped by development of global products and possible new alliances.
Gilead’s Twice-Annual Sunlenca Posts Zero Infection Rate In PrEP Trial
Lenacapavir is halfway to the pivotal data needed to file for twice-annual administration in PrEP, after demonstrating superiority against both background incidence of HIV infections and Truvada.
Asia Deal Watch: Chugai Extends Relationship With Helsinn
Plus deals involving Kissei/JWP, Shionogi/Cilcare, Takeda/Torrent, Genome & Co./Debiopharm, Kaken/J&J, CStone/Ewopharma, MediLink/BioNTech and more.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- OTC, Consumer
-
Biotechnology
- Drug Discovery Tools
- Other Names / Subsidiaries
-
- Shionogi Healthcare Co., Ltd
- Shionogi Pharma Co., Ltd
- Shionogi Techno Advance Research Co., Ltd.
- Shionogi Administration Service Co., Ltd.
- Shionogi Business Partner Co., Ltd
- Shionogi Marketing Solutions Co., Ltd
- Shionogi Career Development Center Co., Ltd.
- Shionogi Digital Science Co., Ltd.
- Shionogi Pharmacovigilance Center Co., Ltd.
- Aburahi AgroResearch Co., Ltd.
- Shionogi Smile Heart Co., Ltd
- UMN Pharma Inc.
- Shionogi B.V.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice